Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
A handful of reports do exist in post-marketing surveillance through the FDA Adverse Event Reporting System, but the post says their causal relationship to the medication remains unclear rather than established
Key Features: Direct analysis of the intact peptide molecule Preserves post-translational modifications (PTMs) Enables identification of isoforms and sequence variants Best Use Case: When complete structural characterization and modification mapping are required
Commonly reported issues include nausea, gastrointestinal discomfort, reduced appetite, and headaches
Importantly, the process does not involve the CYP450 enzyme system, showing no inhibitory or inductive effect on clinically significant isoforms such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4
US$ 28.47
US$ 29.56
US$ 25.75
US$ 26.54
US$ 23.41
US$ 27.96
US$ 24.94
US$ 28.70
